HomeCompareAPLIF vs PLD

APLIF vs PLD: Dividend Comparison 2026

APLIF yields 18181.82% · PLD yields 3.18%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 APLIF wins by $20382968138483965952.00M in total portfolio value
10 years
APLIF
APLIF
● Live price
18181.82%
Share price
$0.01
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20382968138483965952.00M
Annual income
$20,164,798,479,641,134,000,000,000.00
Full APLIF calculator →
PLD
PLD
● Live price
3.18%
Share price
$128.78
Annual div
$4.10
5Y div CAGR
74.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$6.50M
Annual income
$5,256,436.18
Full PLD calculator →

Portfolio growth — APLIF vs PLD

📍 APLIF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAPLIFPLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, APLIF + PLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
APLIF pays
PLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

APLIF
Annual income on $10K today (after 15% tax)
$1,545,454.55/yr
After 10yr DRIP, annual income (after tax)
$17,140,078,707,694,964,000,000,000.00/yr
PLD
Annual income on $10K today (after 15% tax)
$270.62/yr
After 10yr DRIP, annual income (after tax)
$4,467,970.75/yr
At 15% tax rate, APLIF beats the other by $17,140,078,707,694,964,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of APLIF + PLD for your $10,000?

APLIF: 50%PLD: 50%
100% PLD50/50100% APLIF
Portfolio after 10yr
$10191484069241982976.00M
Annual income
$10,082,399,239,820,567,000,000,000.00/yr
Blended yield
98.93%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PLD right now

APLIF
No analyst data
Altman Z
-234.9
Piotroski
4/9
PLD
Analyst Ratings
25
Buy
16
Hold
1
Sell
Consensus: Buy
Price Target
$136.00
+5.6% upside vs current
Range: $119.00 — $155.00
Altman Z
1.9
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

APLIF buys
0
PLD buys
0
No recent congressional trades found for APLIF or PLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAPLIFPLD
Forward yield18181.82%3.18%
Annual dividend / share$2.00$4.10
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%74.4%
Portfolio after 10y$20382968138483965952.00M$6.50M
Annual income after 10y$20,164,798,479,641,134,000,000,000.00$5,256,436.18
Total dividends collected$20368560651224936448.00M$6.37M
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: APLIF vs PLD ($10,000, DRIP)

YearAPLIF PortfolioAPLIF Income/yrPLD PortfolioPLD Income/yrGap
1← crossover$1,828,882$1,818,181.82$11,255$555.24+$1.82MAPLIF
2$312,726,966$310,770,062.56$13,062$1,018.59+$312.71MAPLIF
3$49,997,862,140$49,663,244,286.24$15,903$1,926.67+$49997.85MAPLIF
4$7,474,070,205,933$7,420,572,493,443.65$20,839$3,823.32+$7474070.19MAPLIF
5$1,044,712,232,322,833$1,036,714,977,202,484.10$30,464$8,166.08+$1044712232.29MAPLIF
6$136,547,911,758,351,100$135,430,069,669,765,680.00$52,054$19,457.30+$136547911758.30MAPLIF
7$16,689,313,388,956,088,000$16,543,207,123,374,653,000.00$109,886$54,188.93+$16689313388955.98MAPLIF
8$1,907,542,220,817,720,100,000$1,889,684,655,491,537,200,000.00$304,030$186,451.18+$1907542220817720.00MAPLIF
9$203,896,877,423,206,970,000,000$201,855,807,246,932,000,000,000.00$1,166,125$840,813.32+$203896877423206976.00MAPLIF
10$20,382,968,138,483,967,000,000,000$20,164,798,479,641,134,000,000,000.00$6,504,190$5,256,436.18+$20382968138483965952.00MAPLIF

APLIF vs PLD: Complete Analysis 2026

APLIFStock

Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in the infectious disease in Canada. Its anti-infective portfolio includes Favipiravir for pandemic influenza and COVID-19; ATI-2307, an antifungal candidate, which is in clinical stage for the treatment of cryptococcal meningitis and invasive candidiasis; ATI-1503 that develops a class of gram-negative targeting antibiotics; ATI-1501, a taste-masked liquid oral suspension formulation of an antibiotic, metronidazole; ATI-1801, a novel topical formulation of paromomycin for the treatment of cutaneous leishmaniasis; and ATI-1701 is a live-attenuated vaccine for Francisella tularensis. The company has a strategic alliance with AiPharma Global Holdings LLC for the development of Avigan/Reeqonus (favipiravir). Appili Therapeutics Inc. was incorporated in 2015 and is headquartered in Halifax, Canada.

Full APLIF Calculator →

PLDREIT

Prologis, Inc. is the global leader in logistics real estate with a focus on high-barrier, high-growth markets. As of December 31, 2020, the company owned or had investments in, on a wholly owned basis or through co-investment ventures, properties and development projects expected to total approximately 984 million square feet (91 million square meters) in 19 countries. Prologis leases modern logistics facilities to a diverse base of approximately 5,500 customers principally across two major categories: business-to-business and retail/online fulfillment.

Full PLD Calculator →
📬

Get this APLIF vs PLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

APLIF vs SCHDAPLIF vs JEPIAPLIF vs OAPLIF vs KOAPLIF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.